Page 236 - index.html

staining showed reduced angiogenesis in combination group compared to the control
(p<0.0001) or sorafenib group (p<0.0001) with significantly decreased HIF expression
in tumor tissues. The results from Sirius red staining showed a decrease in fibrosis of
animals treated with ARQ 092 alone (p=0.0004) or with combination of ARQ 092 and
sorafenib (p=0.0001), accompanied with strong downregulation of TGFB, Collagen1 and
ACTA1 expression levels. Granulocyte/T-cells ratio in blood was decreased in all treated
groups compared to the control group and accumulation of neutrophils in liver tissue was
significantly reduced. Western blot analysis of liver tissues showed a significant reduction
of phosphorylation of AKT and its downstream signalling actors mTOR and S6K1 in
both ARQ 092 and combination groups.

Conclusions: Combination of ARQ 092 and sorafenib exerted additive effect in
controlling tumor progression and improved immune response in blood and liver. Our
results confirm the importance of targeting AKT in HCC.
Figure:

ePOSTER ABSTRACTS

Disclosure of Interest: Z. Macek Jilkova: : None Declared, A. Zeybek Kuyucu: : None
Declared, K. Kurma: : None Declared, S. T. Ahmad Pour: : None Declared, G. Roth: :
None Declared, G. Abbadessa: Employee: Conflict with: ArQule Inc, Y. Yu: Employee:
Conflict with: ArQule Inc, V. Leroy: : None Declared, P. Marche: : None Declared, T.
Decaens: : None Declared

236 Programme & Abstracts • HCC Summit